Fox Run Management, L.L.C. Crispr Therapeutics Ag Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$45.39 - $59.0 $105,531 - $137,175	-2,325 Reduced 34.01%	4,511 $204,000
Q2 2023 Aug 11, 2023	BUY	$43.47 - $67.77 $297,160 - $463,275	6,836 New	6,836 $383,000
Q1 2020 May 08, 2020	SELL	$33.68 - $62.53 $179,649 - $333,535	-5,334 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$36.68 - $73.13 $195,651 - $390,075	5,334 New	5,334 $325,000
Q3 2018 Oct 05, 2018	SELL	$44.35 - $65.71 $503,239 - $745,611	-11,347 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$42.62 - $73.59 $483,609 - $835,025	11,347 New	11,347 $667,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.